I. Barneto

发表

Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology

A. Lecube, A. Goday, P. Pérez-Segura, 2017, Clinical and Translational Oncology.

OA13.05 NADIM Study: Updated Clinical Research and Outcomes

N. Viñolas, B. Massuti, M. Provencio, 2019, Journal of Thoracic Oncology.

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression

R. Rosell, M. Taron, N. Reguart, 2009, PloS one.

Increasing dose intensity of cisplatin‐etoposide in advanced nonsmall cell lung carcinoma

A. Tres, C. García-Girón, R. Rosell, 1999, Cancer.

Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract:2007-000067-15; NCTgov: 00478699).

R. Rosell, B. Massuti, J. Sánchez-Payá, 2015 .

Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer.

A. Carrato, C. García-Girón, R. Rosell, 2004, Clinical lung cancer.

Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer.

B. Cirauqui, S. Morales, R. López, 2019, European journal of cancer care.

Prevention of Highly Emetogenic Chemotherapy-Induced Vomiting: A Double Blind, Randomized Crossover Study to Compare Pancopride (LAS 30451) and Pancopride plus Dexamethasone

I. Barneto, E. Aranda, M. Rubio, 1995, Tumori.

Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment.

N. Viñolas, B. Massuti, M. Provencio, 2019, Journal of Clinical Oncology.

Randomized P hase I II S tudy o f G emcitabine-Cisp latin Versus E toposide-Cispla tin i n t he T reatment o f L ocally Advanced o r M etastatic N on-Small-Cell L ung C ancer

A. Carrato, R. Rosell, B. Massuti, 1999 .

Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).

R. Rosell, A. Antón, I. Barneto, 1998, Lung cancer.

Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study.

E. Esteban, I. Barneto, J. Muñoz-Langa, 2015, Future oncology.

Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.

M. Taron, M. Sánchez-Ronco, J. Sánchez, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study.

A. Carrato, J. Garcia-conde, A. Tres, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).

A. Carrato, J. Garcia-conde, I. Barneto, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer.

I. Barneto, E. Díaz-Rubio, E. Aranda, 1990, European journal of cancer.

Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trial.

E. Felip, J. Astudillo, P. Garrido, 2000, Clinical lung cancer.

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

M. Provencio, I. Barneto, J. Valdivia, 2018, BMC Cancer.

Serum levels of intercellular adhesion molecule 1 (ICAM-1) in patients with colorectal cancer: inhibitory effect on cytotoxicity.

I. Barneto, P. Sánchez‐Rovira, E. Aranda, 1998, European journal of cancer.

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.

A. Carrato, R. Rosell, B. Massuti, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study.

A. Carrato, E. Felip, R. Rosell, 2003, Lung cancer.

Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology

A. Lecube, A. Goday, P. Pérez-Segura, 2015, Clinical and Translational Oncology.

PL03.12 Progression Free Survival and Overall Survival in NADIM II Study

J. Bosch-Barrera, M. Provencio, C. Camps, 2022, Journal of Thoracic Oncology.

MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial

J. Bosch-Barrera, M. Provencio, C. Camps, 2022, Journal of Thoracic Oncology.

P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients

N. Viñolas, B. Massuti, M. Provencio, 2019, Journal of Thoracic Oncology.

Simultaneous metastasis of pulmonary adenocarcinoma and bone tuberculosis.

I. Barneto, P. Carpintero, J. Kindelan, 1996, Acta orthopaedica Scandinavica.

Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer

A. Carrato, A. Abad, M. Guillot, 2000, Revista de Oncología.

OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal of Thoracic Oncology.

OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal of Thoracic Oncology.

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.

N. Reinmuth, I. Horváth, K. Syrigos, 2022, The Lancet. Respiratory medicine.

PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial

L. Paz-Ares, T. Ciuleanu, C. Grohé, 2021, Journal of Thoracic Oncology.

Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer.

A. Carrato, R. Rosell, R. Sirera, 2009, Lung cancer.

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

Javier M. Martín-López, J. Bosch-Barrera, N. Reguart, 2023, New England Journal of Medicine.

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

M. Provencio, I. Barneto, J. Valdivia, 2018, BMC Cancer.